Skip to main content

Table 2 Relationship between SUVmax and pAkt/pS6K protein densitometry results and pathological parameters

From: Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer

   SUVmax in the primary tumor Western blotting in primary tumor
   Number=77   Number=77 pAkt (Ser-473) pAkt (Thr-308) pS6K (Ser-235/236)
   mean ± S.D P value mean ± S.D P value mean ± S.D P value mean ± S.D P value
Tissue tumor n=77 6.97 ± 5.96   n=77 3.91 ± 3.01 0.000001 2.83 ± 2.13 0.000009 2.43 ± 1.58 0.000021
non-tumor    n=77 1.00 1.00 1.00
Histological differentiation (Fuhrman grade) G1 n=9 2.72 ± 0.66 0.000073 n=9 1.54 ± 0.57 0.000041 1.21 ± 0.36 0.000089 1.13 ± 0.15 0.000079
G2 n=32 3.90 ± 2.33 n=32 2.57 ± 2.03 2.03 ± 1.57 1.86 ± 1.08
G3 n=29 8.80 ± 3.79 n=29 5.16 ± 2.73 3.46 ± 1.85 2.81 ± 1.23
G4 n=7 18.67 ± 10.23 n=7 8.09 ± 3.49 6.00 ± 2.71 5.19 ± 2.07
pT stage pT1-2 n=43 3.77 ± 2.02 0.000019 n=43 2.43 ± 1.74 0.000029 1.93 ± 1.49 0.000083 1.75 ± 0.95 0.000100
pT3-4 n=34 10.91 ± 6.82 n=34 5.83 ± 3.24 4.00 ± 2.27 3.31 ± 1.79
Microscopic vascular invasion v0 n=28 3.33 ± 1.46 0.000061 n=28 2.08 ± 1.22 0.000100 1.67 ± 1.14 0.000200 1.60 ± 0.78 0.001000
v1 n=49 9.01 ± 6.55 n=49 4.97 ± 3.23 3.50 ± 2.28 2.91 ± 1.72
pN stage N0 n=62 5.58 ± 5.80 0.000053 n=62 3.13 ± 2.54 0.000076 2.41 ± 2.00 0.000200 2.04 ± 1.31 0.000092
N1-2 n=15 12.38 ± 2.59 n=15 7.38 ± 2.45 4.68 ± 1.64 4.14 ± 1.56
Metastasis (cM stage) M0 n=52 4.56 ± 3.59 0.000029 n=52 2.55 ± 2.03 0.000043 2.07 ± 1.69 0.000085 1.81 ± 1.52 0.000078
M1 n=25 12.10 ± 6.78 n=25 7.04 ± 2.53 4.57 ± 2.03 3.85 ± 1.16
cell histology clear cell carcinoma n=57 4.94 ± 3.15 0.000069 n=57 3.16 ± 2.44 0.000500 2.28 ± 1.68 0.000300 2.03 ± 1.19 0.001300
non-clear cell carcinoma n=11 9.44 ± 5.04 n=11 4.43 ± 3.36 3.21 ± 2.11 3.41 ± 2.24
Sarcomatoid* n=9 16.54 ± 9.37 n=9 8.56 ± 1.88 6.17 ± 2.02 3.95 ± 1.59
  1. Data show mean ± S.D.
  2. Sarcomatoid*: clear cell carcinoma with sarcomatoid differentiation.